Serving the Society Since 1986
Advanced Search
Volume 25 Issue 1
February 2010
    Citation: Xue-ling WU, Chun-tao ZHANG, Xiao-ke ZHU, You-chun WANG. Detection of HPV Types and Neutralizing Antibodies in Women with Genital Warts in Tianjin City, China .VIROLOGICA SINICA, 2010, 25(1) : 8-17.  http://dx.doi.org/10.1007/s12250-010-3078-4
    shu

    Detection of HPV Types and Neutralizing Antibodies in Women with Genital Warts in Tianjin City, China

    • 1.

      Department of Cell Biology, National Institute for the Control of Pharmaceutical and Biological Products (NICPBP), Beijing 100050, China

    • 2.

      Department of Sexually Transmitted Disease, Tianjin Center for Disease Control, Tianjin 30001l, China

    • Corresponding author: You-chun WANG, wangyc@nicpbp.org.cn
    • Received Date: 25 May 2009
      Accepted Date: 26 August 2009
      Available online: 01 February 2010
    • The serum samples and corresponding cervical swabs were collected from 50 women with genital warts from Tianjin city, China. The neutralizing antibodies against HPV-16, -18, -58, -45, -6 and -11 in serum samples were tested by using pseudovirus-based neutralization assays and HPV DNAs in cervical swabs were also tested by using a typing kit that can detect 21 types of HPV. The results revealed that 36% (18/50) of sera were positive for type-specific neutralizing antibodies with a titer range of 160-2560, of which 22%(11/50), 12%(6/50), 10%(5/50), 4%(2/50), 4%(2/50) and 2%(1/50) were against HPVs -6, -16, -18, -58, -45 and -11, respectively. Additionally, 60% (30/50) of samples were HPV DNA-positive, in which the most common types detected were HPV-68(18%), HPV-16(14%), HPV-58(12%), HPV-33(8%) and HPV-6, HPV-11, HPV-18 and HPV-52 (6% each). The concordance between HPV DNA and corresponding neutralizing antibodies was 56% (28/50) with a significant difference (P<0.05). The full-length sequences of five HPV types (HPV -42, -52, -53, -58 and -68) were determined and exhibited 98%-100% identities with their reported genomes. The present data may have utility for investigating the natural history of HPV infection and promote the development of HPV vaccines.
    • 加载中

      1. Baay M F, Tjalma W A, Weyler J, et al. 2001. Human papillomavirus infection in the female population of Antwerp, Belgium: prevalence in healthy women, women with premalignant lesions and cervical cancer. Eur J Gynaecol Oncol, 22: 204-208.

      2. Bergeron C, Barrasso R, Beaudenon S, et al. 1992. Human papillomaviruses associated with cervical intrae-pithelial neoplasia. Great diversity and distinct distribution in low-and high-grade lesions. Am J Surg Pathol, 16: 641-649.
          doi: 10.1097/00000478-199207000-00002

      3. Bosch F X, Manos M M, Munoz N, et al. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst, 87: 796-802.
          doi: 10.1093/jnci/87.11.796

      4. Brown D R, Schroeder J M, Bryan J T, et al. 1999. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol, 37: 3316-3322.

      5. Buck C B, Pastrana D V, Lowy D R, et al. 2004. Efficient intracellular assembly of papillomaviral vectors. J Virol, 78: 751-757.
          doi: 10.1128/JVI.78.2.751-757.2004

      6. Calleja-Macias IE, Kalantari M, Allan B, et al. 2005. Papillomavirus subtypes are natural and old taxa: phylogeny of human papillomavirus types 44 and 55 and 68a and -b. J Virol, 78: 6565-6569.

      7. Carter J J, Galloway D A. 1997. Humoral immune response to human papillomavirus infection. Clin Dermatol, 15: 249-259.
          doi: 10.1016/S0738-081X(97)00068-0

      8. Carter JJ, Koutsky LA, Hughes JP, et al. 2000. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis, 181: 1911-1919.
          doi: 10.1086/jid.2000.181.issue-6

      9. Chan S Y, Bernard H U, Ong C K, et al. 1992. Phylogenetic analysis of 48 papillomavirus types and 28 subtypes and variants: a showcase for the molecular evolution of DNA viruses. J Virol, 66: 5714-5725.

      10. Christensen N D, Kreider J W, Shah K V, et al. 1992. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol, 73 (5): 1261-1267.
          doi: 10.1099/0022-1317-73-5-1261

      11. Cui M H, Liu Y Q, Li H L, et al. 1994. Human papillomavirus in condyloma acuminata and other benign lesions of the female genital tract. Chin Med J (Engl), 107: 703-708.

      12. de Villiers E M, Fauquet C, Broker T R, et al. 2004. Classification of papillomaviruses. Virology, 324:17-27.
          doi: 10.1016/j.virol.2004.03.033

      13. Ferrera A, Velema J P, Figueroa M, et al. 1999. Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: a case-control study. Int J Cancer, 82: 799-803.
          doi: 10.1002/(ISSN)1097-0215

      14. Gissmann L. 1996. Immunologic responses to human papillomavirus infection. Obstet Gynecol Clin North Am, 23: 625-639.

      15. Huang S, Afonina I, Miller B A, et al. 1997. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer, 70: 408-411.
          doi: 10.1002/(ISSN)1097-0215

      16. Leiserowitz GS, Hall KS, Foster CA, et al. 1997. Detection of serologic neutralizing antibodies against HPV-11 in patients with condyloma acuminata and cervical dysplasiausing an in vitro assay. Gynecol Oncol, 66: 295-299.
          doi: 10.1006/gyno.1997.4743

      17. Lo K W, Wong Y F, Chan M K, et al. 2002. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer, 100: 327-331.
          doi: 10.1002/(ISSN)1097-0215

      18. Pastrana D V, Buck C B, Pang Y Y, et al. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology, 321: 205-216.
          doi: 10.1016/j.virol.2003.12.027

      19. Phelps W C, Alexander K A. 1995. Antiviral therapy for human papillomaviruses: rational and prospects. Ann Intern Med, 123: 368-382.
          doi: 10.7326/0003-4819-123-5-199509010-00008

      20. Schellekens M C, Dijkman A, Aziz M F, et al. 2004. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol, 93: 49-53.
          doi: 10.1016/j.ygyno.2003.12.015

      21. Sigurdsson K, Taddeo F J, Benediktsdottir K R, et al. 2007. HPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study. Int J Cancer, 121: 2682-2687.
          doi: 10.1002/(ISSN)1097-0215

      22. Stewart A C, Eriksson A M, Manos M M, et al. 1996. Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol, 70: 3127-3136.

      23. zur H H, de Villiers E M. 1994. Human papillomaviruses. Annu Rev Microbiol, 48: 427-447.
          doi: 10.1146/annurev.mi.48.100194.002235

    • 加载中

    Figures(1) / Tables(4)

    PDF

    Article Metrics

    Article views(4257) PDF downloads(13) Cited by()

    Related
    Proportional views

      Detection of HPV Types and Neutralizing Antibodies in Women with Genital Warts in Tianjin City, China

        Corresponding author: You-chun WANG, wangyc@nicpbp.org.cn
      • 1. Department of Cell Biology, National Institute for the Control of Pharmaceutical and Biological Products (NICPBP), Beijing 100050, China
      • 2. Department of Sexually Transmitted Disease, Tianjin Center for Disease Control, Tianjin 30001l, China
      • Received Date: 25 May 2009
      • Accepted Date: 26 August 2009

      Abstract: The serum samples and corresponding cervical swabs were collected from 50 women with genital warts from Tianjin city, China. The neutralizing antibodies against HPV-16, -18, -58, -45, -6 and -11 in serum samples were tested by using pseudovirus-based neutralization assays and HPV DNAs in cervical swabs were also tested by using a typing kit that can detect 21 types of HPV. The results revealed that 36% (18/50) of sera were positive for type-specific neutralizing antibodies with a titer range of 160-2560, of which 22%(11/50), 12%(6/50), 10%(5/50), 4%(2/50), 4%(2/50) and 2%(1/50) were against HPVs -6, -16, -18, -58, -45 and -11, respectively. Additionally, 60% (30/50) of samples were HPV DNA-positive, in which the most common types detected were HPV-68(18%), HPV-16(14%), HPV-58(12%), HPV-33(8%) and HPV-6, HPV-11, HPV-18 and HPV-52 (6% each). The concordance between HPV DNA and corresponding neutralizing antibodies was 56% (28/50) with a significant difference (P<0.05). The full-length sequences of five HPV types (HPV -42, -52, -53, -58 and -68) were determined and exhibited 98%-100% identities with their reported genomes. The present data may have utility for investigating the natural history of HPV infection and promote the development of HPV vaccines.

        HTML